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Abstract
Background: The autoimmune bullous diseases quality of life (ABQOL) questionnaire was recently developed by an
Australian group and has been validated in Australian and North American patient cohorts. It is a 17-item,
multidimensional, self-administered English questionnaire. The study aimed to validate the Chinese version of
the ABQOL questionnaire and evaluate the reliability in Chinese patients.
Methods: The Chinese version of the ABQOL questionnaire was produced by forward-backward translation
and cross-cultural adaptation of the original English version. The ABQOL questionnaire was then distributed to
a total of 101 patients with autoimmune bullous diseases (AIBDs) together with the Dermatology Life Quality
Index (DLQI) and the 36-item Short Form Health Survey (SF-36). Validity was analyzed across a range of indices and
reliability was assessed using internal consistency and test-retest methods.
Results: The Chinese version of the ABQOL questionnaire has a high internal consistency (Cronbach’s alpha coefficient,
0.88) and test-retest reliability (the intraclass correlation coefficient, 0.87). Face and content validity were satisfactory.
Convergent validity testing showed that the correlation coefficients for the ABQOL and DLQI was 0.77 and for the ABQOL
and SF-36 was −0.62. In terms of discriminant validity, there was no significant difference between the proportions of
insensitive items in ABQOL and DLQI (p = 0.236). There was no significant difference between the proportions of
insensitive items in ABQOL and SF-36 (p = 0.823).
Conclusions: The Chinese version of the ABQOL questionnaire has adequate validity and reliability. It may constitute a
useful instrument to measure disease burden in Chinese patients with AIBDs.
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Background
Autoimmune bullous diseases (AIBDs) are a group of dis-
orders characterized by autoantibodies directed against
structural proteins present in the desmosome and hemi-
desmosome of the skin and mucosal membranes. The
AIBDs include various forms of pemphigus, bullous pem-
phigoid (BP), epidermolysis bullosa acquisita (EBA), linear
IgA bullous dermatosis (LABD), dermatitis herpetiformis
(DH), and pemphigoid gestationis (PG) [1]. Blistering le-
sions have a large effect on the quality of life (QOL) [2].
Treatment can also affect the QOL of patients with
AIBDs. For example, the steroids and immunosuppressive
agents used to control AIBDs may cause serious adverse
effects. Therapy-related complications significantly con-
tribute to the mortality in patients with AIBDs [3]. It is
thus of great importance to pay considerable attention to
the patients’ QOL and psychological states as well as clin-
ical status.
Currently, the 36-Item Short Form Health Survey (SF-36)
and the Dermatology Life Quality Index (DLQI) are the
most reported measures to evaluate the QOL of AIBD
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patients. The Chinese versions of the DLQI and SF-36 have
been validated in China [4, 5]. These generic and
dermatology-specific QOL instruments show that patients
with AIBDs have a significant decrease in QOL compared
with the greater population [6, 7]. Recently, a disease-
specific instrument, the AIBDQOL (ABQOL) questionnaire
was developed by an Australian group [8]. It is a 17-item,
multidimensional, self-administered English questionnaire.
Validation in Australian patients showed that the ABQOL
had a moderate correlation with scores on the DLQI and
the General Health subscale of the SF-36 in terms of con-
vergent validity. In terms of discriminant validity, the
ABQOL was found to be more sensitive than the DLQI [8].
The ABQOL was found to be a reliable patient-reported
outcome measure in both Australian and North American
patient cohorts with satisfactory internal consistency (Cron-
bach’s alpha coefficient, 0.84–0.90) and test-retest reliability
(intra-class correlation coefficient, 0.92–0.93) [8, 9]. As the
first validated instrument with the specificity of the
questions maximizing the ability to detect any changes in
disease process, ABQOL questionnaire is a promising dis-
ease specific outcome measure to assess the QOL of
patients with AIBDs [9]. In this study, we aimed to estab-
lish and validate a Chinese version of the ABQOL ques-




AIBDs patients were recruited from the Department of
Dermatology of Shandong Provincial Hospital for Skin
Diseases. Patient inclusion criteria were: at least 18 years
of age, a confirmed diagnosis of an AIBD, and sufficient
education to complete the questionnaire without assist-
ance. All patients with AIBDs were diagnosed according to
clinical manifestations, histopathological findings, direct
and indirect immunofluorescence assay. Indirect immuno-
fluorescence utilized monkey esophagus as substrates.
Pemphigus was also verified by ELISA for desmogleins 1
and 3. BP and PG were verified by BP180-NC16a ELISA
and BP230 ELISA, respectively. EBA was verified by indir-
ect immunofluorescence assay performed on sodium
chloride-split skin and ELISA for type VII collagen. Para-
neoplastic pemphigus (PNP) was verified by a history
tumor and polymorphous mucocutaneous eruption be-
sides immunofluorescence assay.
Forward-backward translation of the ABQOL into Chinese
Permission was obtained from the original English ver-
sion of ABQOL copyright holder. The English ABQOL
was translated into Chinese by a translation company
with the relevant linguistic background. The Chinese
version of the ABQOL was then independently back
translated into English by another certified language
service provider with no access to the original English
questionnaire. The back-translated version was then
reviewed against the originals by the original authors of
the ABQOL and minor revisions were made. Five der-
matologists reviewed the Chinese translation and
reached consensus.
To pilot test and refine the questionnaire, we recruited
10 AIBDs patients to complete the questionnaire. An ex-
perienced interviewer systematically pre-tested patients
by asking them what they thought the question was ask-
ing, what the answers were, and to explain how they de-
cided their answers. Based on the feedback from the 10
patients, we revised several words in the questionnaire
to adapt to the language and culture in China. No points
of misunderstanding were detected. Subsequently, the
final Chinese version of the ABQOL questionnaire was
administered for the study. The English and Chinese
versions of the ABQOL questionnaire are presented in
Additional file 1.
Formal questionnaire
A single investigator administered the survey to reduce
investigator bias. All patients (76 outpatients and 25 in-
patients) completed the Chinese version of the ABQOL
questionnaire without assistance on day 0. The DLQI
and the SF-36 were also completed on day 0 to evaluate
their correlation with the ABQOL. The outpatients were
also asked to take home a stamped addressed envelope
containing the ABQOL questionnaire to complete on
day 7 and return to the investigator. The inpatients com-
pleted the questionnaires on day 7 in the hospital. The
general patient characteristics, including disease stage,
time for completion of the questionnaire, number of
school years completed, profession, and gender were also
recorded.
Reliability
Internal consistency was measured using Cronbach’s
alpha coefficient, which also tested for construct validity
[7]. Test-retest reliability was assessed by comparing the
total ABQOL scores in a subset of patients who com-
pleted the questionnaire on both day 0 and day 7. To re-
duce the recall bias, a 7-day interval was selected for the
retest. The intra-class correlation coefficient (ICC) was
calculated to determine the ability of the tool to give
concordant results at different times.
Validity
Validation of the Chinese version of ABQOL included
the assessment of face, content, construct, convergent,
and discriminant validity [6]. Face and content validity
were established by forward-backward translation of the
ABQOL and by review of the questionnaire by the panel
of bullous disease experts. Convergent validity was
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determined by correlating the ABQOL scores with the
scores obtained from DLQI or SF-36. Discriminant val-
idity was assessed by comparing the proportions of in-
sensitive items in the ABQOL and DLQI (or ABQOL
and SF-36) [8, 10].
Factor analysis
Construct validity was also assessed through factor ana-
lysis [8]. Exploratory factor analysis and principal compo-
nent analysis followed by Oblimin rotation with Kaiser
normalization were performed to assess the dimensional-
ity of the 17 items and to validate the structure of the
Chinese version of the ABQOL questionnaire. Significance
was defined as a loading greater than 0.4 or less than −0.4.
Statistical analysis
All statistical analyses were performed using SPSS v10.01




A total of 101 patients with AIBDs were recruited between
March 2015 and April 2016. All patients completed the
day 0 questionnaire and a subset of 61 patients (60.4%)
completed the day 7 questionnaire. All the participants
declared that there was no obstacle in understanding the
items. Patient demographics are presented in Table 1. Of
the 101 patients recruited, 67 were men and 34 were
women. Patient ages ranged from 18 to 77 years, with a
mean age of 50.02 years. The number of school years
completed ranged from 4 to 18 years, with a mean of
9.37 years. The mean time for completion of the ABQOL
questionnaire was 5.64 min (range 1.37–15.00 min). Most
of the patients had pemphigus vulgaris (PV, n = 57),
followed by BP (n = 25), pemphigus foliaceus (PF, n = 11),
DH (n = 3), LABD (n = 2), EBA (n = 1), PG (n = 1) and
PNP (n = 1). The patient with PNP had a history of thym-
oma resection. The mean (standard deviation, SD)
ABQOL scores for patients with PV was 17.23 (1.35); for
BP, 16.60 (2.09); and for the remaining patients, 17.16
(2.09) (Fig. 1). The mean disease duration of all patients
was 17.82 months (range 10 days to 108 months). The
clinical disease stages were defined as baseline (n = 5),
complete remission during tapering (n = 23), complete re-
mission on minimal therapy (n = 29), complete remission
off therapy (n = 2), control of disease activity (n = 30), par-
tial remission on minimal therapy (n = 1), time to control
of disease activity (n = 8), and relapse/flare (n = 2) [11].
Reliability and validity
The internal consistency and construct validity of the
Chinese version of ABQOL were acceptable, with a
Cronbach’s alpha of 0.88 (Table 2). The test-retest
Table 1 Demographic characteristics of the patient cohort
Variable Value
Age (years), mean (range) 50.02 (18–77)
Course of disease (months), mean (range) 17.82 (0.33–108)
Schooling years (years), (range) 9.37 (4–18)
Completion time (min), mean (range) 5.64 (1.37–15)






Autoimmune bullous disease, n (%)
Pemphigus vulgaris 57 (56.44)
Bullous pemphigoid 25 (24.75)
Pemphigus foliaceus 11 (10.89)
Dermatitis herpetiformis 3 (2.97)
Linear IgA bullous dermatoses 2 (1.98)
Eidermolysis bullosa acquisita 1 (0.99)
Paraneoplastic pemphigus 1 (0.99)
Pemphigoid gestationis 1 (0.99)
Clinical stages, n (%)
baseline 5 (4.95)
complete remission during tapering 23 (22.77)
complete remission on minimal therapy 29 (28.71)
complete remission off therapy 2 (1.98)
control of disease activity 30 (29.70)
partial remission on minimal therapy 2 (1.98)

















Fig. 1 The test-retest reliability of the ABQOL (n = 61)
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reliability of the questionnaire was also acceptable, with
an ICC value of 0.87 (Table 2, Fig. 1). With regard to
convergent validity, the correlation coefficient for the
Chinese ABQOL and DLQI was 0.77 (p < 0.001), indi-
cating a moderate correlation between the ABQOL
and DLQI. The correlation coefficient for the Chinese
ABQOL and SF-36 was −0.62 (p < 0.001). There was
no significant difference in the proportion of insensi-
tive items between ABQOL and DLQI (Fisher exact
test, p = 0.236), or between ABQOL and SF-36 (the
Pearson Chi-square test, p = 0.823). Statistical analyses
of validity and reliability measures are presented in
Table 2.
Factor analysis
The Kaiser-Meyer-Olkin measure of sampling adequacy
(0.804) and the Bartlett test of sphericity (p < 0.001) sug-
gested that factor analysis of the data was appropriate
[12]. The Catell scree plot suggested that three factors
(symptom, mucosal, and psychosocial) should be
retained, representing 53.51% of the cumulative variance.
The rotation matrix obtained by the exploratory princi-
pal components analysis followed by Oblimin rotation
[12] indicated that nine items loaded on symptom sub-
scale (questions 1, 2, 3, 4, 5 and 9, 10, 11, 12); two items
loaded on mucosal subscale (questions 6 and 7); and six
items loaded on psychosocial subscale (questions 8, 13,
14, 15, 16, 17). The three dimensions represented are
shown in Table 3.
Discussion
In the present study, we established a Chinese version of
the ABQOL questionnaire and performed reliability and
validity tests of this questionnaire in a Chinese cohort of
AIBDs patients. Our results showed a little higher in-
ternal consistency with a Cronbach’s alpha of 0.88 than
the value validated in the Australian cohort (0.84) where
the original English ABQOL was developed [8]. The
English ABQOL has also been validated in a North
American patient cohort with satisfactory internal
consistency (Cronbach’s alpha coefficient, 0.90). It is
Table 2 Validity and reliability for the ABQOL











Correlation with DLQI r = 0.77, p < 0.001
Correlation with SF-36 r = −0.62, p < 0.001
Discriminant
validity
DLQI p = 0.236
SF-36 p = 0.823
Internal
consistency
Cronbach’s alpha alpha = 0.88
Test-retest
reliability
ICC r = 0.87
Abbreviations: ABQOL Autoimmune Bullous Disease Quality of Life
Questionnaire, DLQI Dermatology Life Quality Index, SF-36 Medical
Outcome Study 36-item short-form questionnaire, ICC intraclass correlation
coefficient
Table 3 The principal component and factor analysis of the Chinese version of ABQOL
Question No. Description of item Factor 1 symptoms Factor 2 mucosal Factor 3 psychosocial
1 pain .796 .038 -.162
2 itch .765 -.228 -.096
3 clothing changes .521 .212 -.030
4 healing .664 .026 .042
5 bathing or showering .736 -.044 .089
6 pain (mouth) .027 .817 .034
7 gingival bleeding .091 .711 -.002
8 food avoidance .053 .270 .360
9 embarrassment .473 .136 .395
10 depression .582 .278 .124
11 anxiety .524 .270 .151
12 family/friends .494 -.321 .406
13 sexual activity .263 .077 .571
14 relationships -.023 -.395 .844
15 social life .325 .253 .487
16 work and study .112 .417 .506
17 discrimination -.170 .254 .616
Extraction method: principal components analysis; rotation method: Oblimin with Kaiser normalization; Bold items load on the assigned factor
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known that a Cronbach’s alpha of above 0.70 would be
ideal to evaluate the reliability of patient-reported mea-
sures for internal consistency of a questionnaire [13].
Thus, this version of Chinese ABQOL questionnaire will be
a reliable patient-reported outcome measure for evaluating
the QOL of Chinese AIBDs patients. In addition to the reli-
ability, a Cronbach’s alpha of 0.88 also indicates that this
Chinese version of ABQOL has satisfactory construct valid-
ity. The test-retest reliability coefficient of our questionnaire
was 0.87, close to the values in the original study and in the
North American cohort (intra-class correlation coefficient,
0.92 and 0.93, respectively). This data suggest that the
Chinese ABQOL questionnaire will yield consistent results
under similar conditions.
We noticed that more men were recruited in this study.
This gender bias would attribute to that AIBDs usually af-
fects the elderly and the differential educational levels be-
tween the men and women aged people in China. Most of
the older adults in China, especially women, are poorly
educated. In contrast, ABQOL is a self-reported question-
naire. Many elder Chinese women AIBDs patients could
not completed the questionnaire by themselves and thus,
these patients were excluded. Most of the patients were in
the category of PV (n = 57, 56.4%) and BP accounted for
24.8% (25 of 101), with the remaining in other categories.
The ABQOL scores for patients with PV was 17.23 ±
1.35; for BP, 16.60 ± 2.90; and for the remaining pa-
tients, 17.16 ± 2.09. In contrast, the Australian cohort
in the validation of the original ABQOL composed of
40% PV (28 of 70), 35.7% BP, and 24.3% of others. The
mean (SD) ABQOL scores for patients in the three cat-
egories were 11.5 (5.5), 8.4 (5.5), and 11.9 (8.9), respect-
ively. The North American cohort enrolled 39 patients,
composed of 46.1% PV (n = 18), 28.2% BP (n = 11), and
25.6% of others. The ABQOL scores for PV and BP
were 16.4 ± 2.9 and 10.8 ± 2.5, respectively. Thus, PV is
more prevalent in our cohort and these patients had a
higher mean ABQOL scores than those in the original
validation study of the ABQOL while similar to those
in the North American cohort. In contrast, the BP pa-
tients in our study had higher ABQOL scores than
those in the other two studies. These differences might
contribute to the different internal consistency of the
questionnaire in the three cohorts.
Before the launching of the newly developed ABQOL
for AIBDs patients, generic and dermatology-specific
QOL instruments were utilized to monitor disease activ-
ity and to evaluate the effectiveness of care. The Medical
Outcomes Study SF-36 and the dermatology-specific
DLQI have acknowledged the significant decrease in
QOL of patients with AIBDs compared with the greater
population. Paradisi et al. found that patients with pem-
phigus had a markedly impaired overall QOL compared
with healthy subjects [14]. There was a significant
association between disease severity and lower SF-36
scores in these patients. High prevalence of psychiatric
comorbidity was also observed in pemphigus patients
[15]. In addition to the SF-36, DLQI and General Health
Questionnaires have also been used to monitor the QOL
and psychological status of patients with pemphigus vul-
garis [7, 16, 17].
Patients with symptom of itching and severe skin in-
volvement had worse QOL and there was a negative cor-
relation between DLQI score and duration of the disease
[7]. Pemphigus patients were also recorded to have the
psychiatric morbidity rates at 40% by GHQ-12 and 26%
by ICD-10 [16, 17]. Besides pemphigus, the QOL of other
AIBDs patients including BP and DH were also severely
impaired as assessed by DLQI [18]. The newly developed
ABQOL, however, was found to be more sensitive than
the DLQI in determining the disease activity (p < 0.02) in
the initial evaluation [8]. This ABQOL explores greater
depth in a corresponding domain than that in a generic
measure, enabling a heightened responsiveness to any
changes that may occur. We revealed moderate to good
convergence between the Chinese version of ABQOL and
DLQI instruments (convergent validity, r = 0.77), even
slightly higher than that found in the original study (0.64).
The correlation coefficient (−0.62, p < 0.001) between the
ABQOL and SF-36 was also higher than that observed in
the original study (0.51) [8].
Similar as the original ABQOL study, the 17 items of the
questionnaire were also classified as factors of three cat-
egories: psychological, physical, and social factors. How-
ever, there is an interesting difference in the categories of
the item ‘food avoidance’ (question 8) between the Chinese
version and the original ABQOL. In the original develop-
ment of the ABQOL in Australia, this item was classified
as a physical factor, meaning the hardness of the food may
destroy the mucous membrane of the esophagus of the
AIBDs patients. However, due to the Chinese traditional
culture, food avoidance in the Chinese version of ABQOL
is rather a behavior method for avoidant of certain food.
The original literature had validated that the disease-
specific QOL instruments are more sensitive to changes in
clinical status than general QOL measures [10]. However,
in our study, there were 7, 7, and 18 insensitive items in
the ABQOL, DLQI, and SF-36, respectively. The ABQOL
was not more sensitive than SF-36 (p = 0.823) and DLQI
(p = 0.236). The cultural difference and the poor schooling
years were the likely reasons. For example, the word ‘holi-
day’ is an unfamiliar concept to many Chinese patients, es-
pecially to the rural patients. However, it is hard to find a
more suitable word to replace it, we thus still use the ori-
ginal word ‘holiday’.
There are several limitations to this study. First, as the
patients were recruited from a single hospital there might
be patient selection bias. Second, the correlation between
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ABQOL and Autoimmune Bullous Skin Disorder Intensity
Score (ABSIS), pemphigus disease area index (PDAI) or
Bullous Pemphigoid Disease Area Index (BPDAI) [19] was
not included in the study. A recently study illustrated that
BPDAI was correlated with ABQOL [20].
Conclusion
Our study findings indicate that the Chinese version of
the ABQOL questionnaire has adequate validity and reli-
ability. It can be used to monitor the disease activity of
Chinese patients with AIBDs.
Additional file
Additional file 1: ABQOL questionnaire. (DOC 68 kb)
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